MwanzoP8A • SGX
add
Cordlife Group Ltd
Bei iliyotangulia
$ 0.16
Bei za mwaka
$ 0.12 - $ 0.46
Thamani ya kampuni katika soko
41.47M SGD
Wastani wa hisa zilizouzwa
elfu 24.84
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
SGX
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (SGD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 4.60M | -67.54% |
Matumizi ya uendeshaji wa biashara | 8.59M | -6.80% |
Mapato halisi | -6.18M | -655.33% |
Kiwango cha faida halisi | -134.45 | -1,810.56% |
Mapato kwa kila hisa | — | — |
EBITDA | -6.84M | -615.37% |
Asilimia ya kodi ya mapato | 8.73% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (SGD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 59.54M | -15.89% |
Jumla ya mali | 224.31M | -4.16% |
Jumla ya dhima | 101.27M | 3.31% |
Jumla ya hisa | 123.03M | — |
hisa zilizosalia | 256.31M | — |
Uwiano wa bei na thamani | 0.32 | — |
Faida inayotokana na mali | -8.79% | — |
Faida inayotokana mtaji | -15.66% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (SGD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -6.18M | -655.33% |
Pesa kutokana na shughuli | -2.95M | -192.71% |
Pesa kutokana na uwekezaji | 2.90M | 258.76% |
Pesa kutokana na ufadhili | elfu -549.50 | -19.59% |
Mabadiliko halisi ya pesa taslimu | elfu -498.00 | -153.06% |
Mtiririko huru wa pesa | -4.65M | -1,473.26% |
Kuhusu
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2 Mei 2001
Tovuti
Wafanyakazi
111
